Evidence map›Paper›PMID 30584660›Full record

ArticleHepatology (Baltimore, Md.)2019

Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation.

Austin Moore, Linwei Wu, Jen-Chieh Chuang, Xuxu Sun, Xin Luo, Purva Gopal, Lin Li, Cemre Celen, Michael Zimmer, Hao Zhu

Open access · greenAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. iScience · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Austin MooreChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-3816-4524
Linwei WuChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Jen-Chieh ChuangChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Xuxu SunChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Xin LuoChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Purva GopalDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
Lin LiChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Cemre CelenChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Michael ZimmerBiology, Catabasis Pharmaceuticals, Cambridge, MA.
Hao ZhuChildren's Research Institute, Departments of Pediatrics and Internal Medicine, Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-8417-9698
The University of Texas Southwestern Medical Center · USCatabasis Pharmaceuticals (United States) · USThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

Cancer Biology Training GrantT32CA124334 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI SHAY, JERRY WILLIAM · 2007 to 2021
$5.3M
Enhancing mammalian liver repair and regenerationR01DK111588 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI ZHU, HAO · 2017 to 2020
$1.5M
Sample Size Method and Software Development in Survival Trial with a Cure RateR03CA150077 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ZHANG, JIAJIA · 2010 to 2011
$158k
American Association for Cancer Research SU2C-AACR-IRG-10-16Cancer Prevention and Research Institute of Texas CPRIT RP150596Cancer Prevention and Research Institute of Texas D P150077Fundamental Research Funds for the Central Universities 17ykjc09Howard Hughes Medical Institute MedicalNational Natural Science Foundation of China 81670592NCI NIH HHS T32 CA124334NIDDK NIH HHS R01 DK111588
6 · The paper itself

Abstract

Nonalcoholic steatohepatitis (NASH) is a rapidly growing cause of chronic liver damage, cirrhosis, and hepatocellular carcinoma. How fatty liver pathogenesis is subject to epigenetic regulation is unknown. We hypothesized that chromatin remodeling is important for the pathogenesis of fatty liver disease. AT-rich interactive domain-containing protein 1A (ARID1A), a DNA-binding component of the SWItch/sucrose nonfermentable adenosine triphosphate-dependent chromatin-remodeling complex, contributes to nucleosome repositioning and access by transcriptional regulators. Liver-specific deletion of Arid1a (Arid1a liver knockout [LKO]) caused the development of age-dependent fatty liver disease in mice. Transcriptome analysis revealed up-regulation of lipogenesis and down-regulation of fatty acid oxidation genes. As evidence of direct regulation, ARID1A demonstrated direct binding to the promoters of many of these differentially regulated genes. Additionally, Arid1a LKO mice were more susceptible to high-fat diet-induced liver steatosis and fibrosis. We deleted Pten in combination with Arid1a to synergistically drive fatty liver progression. Inhibition of lipogenesis using CAT-2003, a potent sterol regulatory element-binding protein inhibitor, mediated improvements in markers of fatty liver disease progression in this Arid1a/Pten double knockout model. Conclusion: ARID1A plays a role in the epigenetic regulation of hepatic lipid homeostasis, and its suppression contributes to fatty liver pathogenesis. Combined Arid1a and Pten deletion shows accelerated fatty liver disease progression and is a useful mouse model for studying therapeutic strategies for NASH.

Indexed as

LipogenesisAnimalsDNA-Binding ProteinsFatty AcidsLiverMiceMice, KnockoutMolecular Targeted TherapyNon-alcoholic Fatty Liver DiseaseOxidation-ReductionPTEN PhosphohydrolaseSterol Regulatory Element Binding ProteinsTranscription FactorsArid1a protein, mouseDNA-Binding ProteinsFatty AcidsPTEN PhosphohydrolasePten protein, mouseSterol Regulatory Element Binding ProteinsTranscription Factors

Identifiers

PMID30584660
PMCPMC6461494
OpenAlexW2906064349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.